论文部分内容阅读
目的:了解二甲双胍联合吡格列酮(PGZ)治疗2型糖尿病(T2DM)的疗效及优点。方法:将60例T2DM患者随机分为二甲双胍联合格列齐特组(A组)、二甲双胍联用PGZ组(B组),进行6个月治疗,测定治疗前后血压(BP)、血糖(PG)、体重指数(BMI)、糖化血红蛋白(HbA1C)、胰岛素(Ins)、血脂等指标,并计算胰岛素抵抗指数(HOMA-IR)。结果:两组治疗均可使BP、PG、BMI、HbA1C及LDL-C下降(P<0.05),但B组同时可使INS水平下降(P<0.05),HOMA-IR降低(P<0.01)。结论:二甲双胍联用PGZ可改善T2DM患者的糖脂代谢紊乱,并降低血压,减轻体重,同时改善胰岛素抵抗(IR)。
Objective: To investigate the efficacy and advantages of metformin combined with pioglitazone (PGZ) in the treatment of type 2 diabetes mellitus (T2DM). Methods Sixty patients with T2DM were randomly divided into two groups: metformin combined with gliclazide (A) and metformin combined with PGZ (B) for 6 months. The blood pressure (BP), blood glucose (PG) , Body mass index (BMI), HbA1C, Ins, lipids and other indicators, and calculate the insulin resistance index (HOMA-IR). Results: The levels of BP, PG, BMI, HbA1C and LDL-C in both groups decreased significantly (P <0.05) . Conclusion: Metformin combined with PGZ can improve glucose and lipid metabolism disorders, lower blood pressure, reduce body weight and improve insulin resistance (IR) in T2DM patients.